Avalo Therapeutics announced on September 22, 2025, the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings over 20 years of leadership experience in capital markets, strategy, business development, and company building within the life sciences sector. His appointment is expected to bolster Avalo's strategic and financial oversight.
Mr. Lind most recently served as President, Chief Executive Officer, and Board Member of Longboard Pharmaceuticals, where he guided the company to a multi-billion-dollar exit, including its $2.6 billion acquisition by H. Lundbeck A/S in 2024. Prior to Longboard, he was Executive Vice President and Chief Financial Officer at Arena Pharmaceuticals.
His experience includes raising over a billion dollars in capital to support innovative biotech companies. Mr. Lind's expertise in unlocking and delivering shareholder value through sound financial and corporate strategy will be crucial as Avalo advances AVTX-009 through its Phase 2 LOTUS trial and explores future growth opportunities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.